Here is a post I made on the other message board concerning

New Post Public Reply Private Reply Replies (3) Message Board
plutonium gman3 #6773
459
Here is a post I made on the other message board concerning DECN's termination of the registration statement and my take on the state of things.

I hope I'm wrong with my opinion and see this company grow. I guess only time will tell.

IMO the company will be snatched up before it organically grows. There are rumors throughout the industry that that one of these mega pharmas was prepared to take control of DECN for less than $6 million. And Mr. Berman stopped it. Does TAUG's failed paid consultant need a primer on basic arithmetic? I could provide it. We have discussed the goings on in Beverly Hills, CA, now let's keep our eyes on Pittsburg, PA.


Let me give the penny traders a lesson on their inconsequential existence.

DECN has, according to OTCMarkets, 140 million shares outstanding. If our M&A giant was ready to acquire lets say 15 million shares in the open market, lets say 10 million shares to the disbelieving followers of TAUG's failed paid consultant. Then once the SEC declared DECN's registration statement qualified, the M&A giant would buy the entire thing, all 150 million shares for $5 million. That would give our M&A giant a total of 160 million shares of a total of 290 million shares outstanding. Since Preferred stock has no share voting rights, and Notes have no voting rights, our M&A giant would control DECN for a total outlay of $5.2 million dollars.

Our M&A giant could then demand, that as controlling shareholders, a wholesale change of the BOD and the installation of their own CEO. Like I have said many times, DECN as a public company, no matter the uber anger of TAUG's failed paid consultant and his abject hatred of CEO Berman, would give in to the demand, and about 14 days from the SEC declaring the registration statement confirmed, the M&A giant would control DECN. And their first order of business, pay themselves back the $5 million. And who would still be around to stop it?

So here comes the basic arithmetic for TAUG's failed paid consultant. DECN is worth lets say $8 million currently, $.059 X 140 million shares. Add to that $5 million and make the total outstanding 290 million shares. 290 million into $13 million comes to $.045 per share. Next exercise, sell DECN's technology directly to the M&A giant leaving DECN with perhaps $1 million in the bank, no technology and no future. Just enough $$ to keep the shell alive for 6 months and 1 day to skirt the bankruptcy preference period.

So, at the end of this exercise, TAUG's failed paid consultant would have lowered the value of his daddy's stock, and made the penny traders even more inconsequential then they are now.

Good job Johnny. Way to think this through. Berman figured this out weeks ago, opened dialog with the M&A giant, brought in a second M&A giant for some competition and hopefully some life happily ever after. And the penny traders --- well they will still call Mr. Berman names and chase those two pennies.

Decision Diagnostics Corp (DECN) Stock Research Links

DECN Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Piedmont Orthopedics Expands Care in Henry County

Updated Category News Views 37

A Surgeon's Story Comes to Henry County Ah, the medical field. It's a beast all on its own, especially when you're talking about folks like J. Hunter Matthews, M.D. making waves in the orthopedic world. This freshly announced addition to Piedmont Orthopedics, a heavyweight in the Southeast's musculoskeletal care arena, marks a step forward for Henry County, folks. We're...

Continue Reading
Foodcare Proves Effective in Reducing Blood Sugar Levels

Updated Category News Views 6

A New Chapter for Diabetes Care: Foodcare Folks, we've got ourselves a game-changer in the world of diabetes care. Listen closely: Foodsmart's latest study, hot off the press from the American Heart Association's Circulation, essentially hands over the blueprint for tackling type 2 diabetes in an innovative fashion. Now, I'm not the type to get all mushy over scientific...

Continue Reading
Guaranteed Roof Expands with EM Exteriors through LB Capital

Updated Category News Views 5

A Bold Move to Elevate Roofing Standards In a move that seems to jolt the roofing industry awake, Guaranteed Roof is taking the wraps off its new strategic partnership with LB Capital and EM Exteriors. Think of it as a power trio aiming to redefine what roofing solutions should mean in the Southeast. It’s the kind of news that makes you sit up and ask, why now and why...

Continue Reading
EnGenius Names Experienced VP to Boost Sales Growth

Updated Category News Views 3

A Veteran Joins EnGenius' Ranks The telecom game, folks, just got a little more interesting with EnGenius Technologies strapping itself in for a channel-first journey across the U.S. and Canada. They've placed a seasoned player, Rachel Saunders, into the cockpit as Vice President of Sales, North America. Her resume reads like a telecom scout's dream: 17 years in electric...

Continue Reading
Donatos Targets Texas: Pushing Franchise Growth Limits

Updated Category News Views 7

Donatos Pizza: Ambitious Expansion in the Lone Star State When you think about pizza chains expanding, Donatos Pizza might not be the first name to come to mind, but they're cooking up something big in Texas. Folks in Dallas and Houston better be ready because Donatos is rolling out the red carpet for its edge-to-edge, topping-loaded pies all over Texas. Strategic Growth:...

Continue Reading
American Savings Bank Surges 6% on NYSE Debut

Updated Category News Views 6

American Savings Bank Lands with a Bang on NYSE Who would have thought American Savings Bank's (NYSE: ASBH) entry onto the stock market would start with such gusto? It's not every day you see a debut that impressive, with shares soaring 6.25% right out of the gate. Guess it's safe to say the folks over at ASBH did something right in the lead-up to their NYSE launch. CEO...

Continue Reading
Airswift's Strategic Acquisition Boosts U.S. Energy Presence

Updated Category News Views 6

What's Driving Airswift's Latest Expansion? Airswift just dropped a bombshell by snapping up key businesses from New Tech Global (NTG), marking a serious power move in the U.S. energy sector. Now, what does this actually mean for investors? In blunt terms: they're muscling up their contractor base by a meaty 30%. That's no small feat. It's a calculated step to ace the...

Continue Reading
Omneky Integrates AI Growth Agent With Slack for Ads

Updated Category News Views 5

Omneky's New Move: AI Growth Agent Meets Slack Picture this: You've got a marketing team hustling in the digital age, and now they've got a new ally. Omneky, the big-wig in autonomous AI growth, has snuck its AI Growth Agent right into Slack. This isn't just a party trick during Dreamforce week in San Francisco. This is Omneky throwing another cog into the advertising...

Continue Reading
Chad Tucker's Sequel Explores Deep Spiritual Themes

Updated Category News Views 6

An Honest Take: Faith, Growth, and Surrender A player in the world of spiritual growth literature has stepped up again, and it ain't holding back. Chad Tucker, a name perhaps familiar to folks following transformation tales soaked with faith, has released a beefy sequel to his first hit: The Lord in Us: If You Can Love an Enemy, You Can Love Anyone. Well, now he's back...

Continue Reading
Metriport Eyes Major Step in Health Data Integration

Updated Category News Views 6

Metriport's Push into the TEFCA Framework Son of a gun, Metriport's making noise in the health data world! They just got the nod as a Candidate QHIN under the Trusted Exchange Framework and Common Agreement, or TEFCA if you're into acronyms. This isn't just some digital high-five; it's a significant stride forward for healthcare data exchange. Now they're smack in the...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring ASC47: A Promising Therapy that Combines with Tirzepatide

Updated Category News Views 155

ASC47 and Tirzepatide Combination: A Breakthrough in Weight Management Recently, Ascletis Pharma Inc. has shared some exciting findings about its innovative treatment strategy for obesity, specifically involving the combination of ASC47 and tirzepatide. In studies conducted on diet-induced obese (DIO) mice, the duo demonstrated remarkable efficacy, leading to greater...

Continue Reading
Denali and Royalty Pharma Secure $275 Million Royalty Agreement

Updated Category News Views 156

Denali Therapeutics and Royalty Pharma Collaborate on Funding Deal Denali Therapeutics Inc. (NASDAQ: DNLI) and Royalty Pharma plc (NASDAQ: RPRX) have recently announced a significant synthetic royalty funding agreement worth $275 million. This deal is primarily focused on future net sales of the investigational medication tividenofusp alfa. This collaboration aims to...

Continue Reading
Kohler Resort's New Golf Course and Facility Upgrades

Updated Category News Views 359

Kohler Resort Introduces Exciting New Additions Kohler, a luxury hospitality destination, is embarking on an exciting new chapter of growth and innovation. This beautiful resort, famed for its world-class amenities and stunning natural surroundings, has announced several transformative additions to elevate guest experiences and positively impact the local community. A...

Continue Reading
CerraCap Backs MazeBolt's AI DDoS Platform Push

Updated Category News Views 14

Stepping Into the Cybersecurity Arena When giants like CerraCap Ventures make a move, you better believe there's something worth watching. Their recent investment in MazeBolt isn't just another line on a balance sheet—it's a bold statement about where cybersecurity is heading. This isn't child's play. We're talking next-gen resilience against DDoS threats, powered by...

Continue Reading
Investigation Launched into Simulations Plus, Inc. Shares

Updated Category News Views 183

Understanding the Securities Class Action Investigation The Rosen Law Firm, known for advocating for investor rights, has initiated an investigation concerning potential securities claims for shareholders of Simulations Plus, Inc. (NASDAQ: SLP). This action arises from allegations suggesting the company may have disseminated materially deceptive business information to...

Continue Reading